Although PLK1 is known to be regulated by key oncogenic pathways, such as AURKA (which phosphorylates Thr137 /210 to activate PLK1 during G2/M phase) [54], FOXM1 (which binds the PLK1 promoter to enhance transcription) [55], and E2F1 (which activates PLK1 expression in prostate cancer by promoting the transcription of ORC6) [56], Our findings uncover a previously unrecognized TRIM47-PLK1 regulatory axis, in which TRIM47 modulates PLK1 primarily through ubiquitination-related mechanisms. Here, ORC6 is linked to prostate carcinoma.